Amanta Healthcare Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 5,000,000 (50%) | — | ₹6,300 Cr |
| NII (HNI) | — | 1,500,000 (15%) | — | ₹1,890 Cr |
| Retail | — | 3,500,000 (35%) | — | ₹4,410 Cr |
| Σ Total | — | 10,000,000 (100%) | — | ₹126,000 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 119 | ₹14,994 |
| Retail (Max) | 13 | 1,547 | ₹194,922 |
| S-HNI (Min) | 14 | 1,666 | ₹209,916 |
| B-HNI (Min) | 67 | 7,973 | ₹1,004,598 |
Financial Statements Amount in Crore
| Metric | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 276 | 282 | 263 |
| EBITDA | 61 | 59 | 56 |
| Profit After Tax | 11 | 4 | -2 |
| Net Worth | 96 | 66 | 63 |
| Total Assets | 382 | 352 | 374 |
| Reserves & Surplus | 68 | 39 | 36 |
| Total Borrowing | 195 | 205 | 216 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat – 70.00
- 2 Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat – 30.13
- 3 General corporate purposes – 6.60
Company Overview
Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products, specifically parenteral products, which are packaged in plastic containers utilizing Aseptic Blow-Fill-Seal (“ABFS”) and Injection Stretch Blow Moulding (“ISBM”) technologies. The company is also a manufacturer of medical devices.
The company manufactures fluid therapy formulations, including IV fluids, diluents, ophthalmic solutions, and respiratory care products. It also offers irrigation solutions, first-aid products, and eye lubricants in the medical device segment.
The company markets products through three business units:
- National sales,
- International sales and
- Product partnering with various foreign and Indian pharmaceutical companies.
The company manufactures over 45 generic products, marketing them under their brands in India through 320 distributors and stockists.
The company sells products in Africa, Latin America, the UK, and beyond. Its products are registered in 19 countries and comply with various regulations. In Fiscal 2025, the company exported branded products to 21 countries.
As of March 31, 2025, the company has a team of 1,718 employees at its formulation and development and quality laboratory.
Competitive Strengths
- Well-established manufacturer of pharmaceutical formulations with a diverse product portfolio and diverse market.
- Large manufacturing capabilities
- Wide Domestic and International Marketing Network.
- Experienced management team supported by a large, diverse and skilled workforce.